DNTH vs PSA · rev $6.2M vs rev $4.82B
Dianthus Therapeutics Inc. (DNTH) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
DNTH currently screens at market cap $4.40B. PSA currently screens at market cap $0.
Not investment advice. Open the DNTH and PSA stock pages for the full models.
Not investment advice.